hyou645.indd
|
|
|
- はすな かんざとばる
- 9 years ago
- Views:
Transcription
1
2 no.645 vol.63 no ACP ACP f CODE CN1645
3
4 TRUTH SEEKING
5 ATM INDEX NATURE REVIEWS DRUG DISCOVERY, VOLUME12, DECEMBER (2013) 2014 Access to Medicine Index. Access to Medicine Foundation
6 3 CLINICIAN Ê16 NO. 645
7 CLINICIAN Ê16 NO
8 5 CLINICIAN Ê16 NO. 645
9 CLINICIAN Ê16 NO
10 7 CLINICIAN Ê16 NO. 645
11 CLINICIAN Ê16 NO
12 9 CLINICIAN Ê16 NO. 645
13 CLINICIAN Ê16 NO inph inph inph inph possible inph possible inph probable inph possible inph probable inph definite inph
14 11 CLINICIAN Ê16 NO. 645 inph Hirono N, et al:distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci, 11, DESH inph
15 (2015) 2):an open-label randomised trial. Lancet Neurol, 14, idiopathic normal pressure hydrocephalus (SINPHONI- Kazui H, et al:lumboperitoneal shunt surgery for (2013) hydrocephalus after shunt surgery. J Neurol Sci, 328, symptoms in patients with idiopathic normal pressure Kazui H, et al : Predictors of the disappearance of triad Brain and Nerve Neurologia medico-chirurgica, 52, (2012) normal pressure hydrocephalus :second edition. Mori E, et al : Guidelines for management of idiopathic (2013) multiple hospitals. Int Psychogeriatr, 25, symptoms in patients with dementia : a cohort study in stay for the treatment of severe neuropsychiatric Sugiyama H, et al :Predictors of prolonged hospital (1999) CLINICIAN Ê16 NO
16 13 CLINICIAN Ê16 NO. 645
17 CLINICIAN Ê16 NO
18 CT DVD NST /ARB FAX 15 CLINICIAN Ê16 NO. 645
19 M M CT scan CT ECG CT CT ECG CLINICIAN Ê16 NO
20 17 CLINICIAN Ê16 NO. 645 Hand book,
21 CLINICIAN Ê16 NO inform inform
22 19 CLINICIAN Ê16 NO mg mg mg mg.. mmhg mmhg 180/110
23 CLINICIAN Ê16 NO Brose M, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer :a randomized, double-blind, phase 3 trial. Lancet, 384 (9940), (2014) Schlumberger M, et al :Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med, 372 (7), (2015) Team Nexavar
24 21 CLINICIAN Ê16 NO. 645 Advance Care Planning
25 CLINICIAN Ê16 NO
26 23 CLINICIAN Ê16 NO. 645
27 CLINICIAN Ê16 NO
28 25 CLINICIAN Ê16 NO. 645
29 CLINICIAN Ê16 NO
30 27 CLINICIAN Ê16 NO. 645
31 CLINICIAN Ê16 NO high resolution manometry
32 29 CLINICIAN Ê16 NO. 645
33 CLINICIAN Ê16 NO Yoshikawa H, et al:oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol, 47, (2012) Adachi K, et al :Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol, 16, (2001) Mizuta A, et al:different sex-related influences of eating habits on the prevalence of reflux esophagitis in Japanese. J Gastroenterol Hepatol, 26, (2011)
34 31 CLINICIAN Ê16 NO. 645 Nutritional Support Team Inflammatory bowel disease
35 CLINICIAN Ê16 NO
36 33 CLINICIAN Ê16 NO. 645
37 CLINICIAN Ê16 NO IBD IBD IBD IBD IBD 2030
38 35 CLINICIAN Ê16 NO. 645
39 CLINICIAN Ê16 NO Treat to Target csdmard
40 37 CLINICIAN Ê16 NO. 645 csdmard csdmard MSW RA
41 CLINICIAN Ê16 NO
42 39 CLINICIAN Ê16 NO. 645
43 CLINICIAN Ê16 NO benefit pt-global-vas unmet medical needs
44 41 CLINICIAN Ê16 NO. 645
45 CLINICIAN Ê16 NO
46 43 CLINICIAN Ê16 NO
47 CLINICIAN Ê16 NO
48 45 CLINICIAN Ê16 NO. 645 Interdisciplinary
49 CLINICIAN Ê16 NO Barsky AJ, Borus JF:Functional somatic syndromes. Ann Intern Med, 130 (11), (1999) Del Fabbro E : Assessment and management of chemical coping in patients with cancer. JCO, 32, (2014)
50 47 CLINICIAN Ê16 NO. 645
51 CLINICIAN Ê16 NO
52 49 CLINICIAN Ê16 NO. 645
53 CLINICIAN Ê16 NO
54 51 CLINICIAN Ê16 NO. 645
55 CLINICIAN Ê16 NO
56 53 CLINICIAN Ê16 NO. 645
57 CLINICIAN Ê16 NO
58 55 CLINICIAN Ê16 NO. 645
59 CLINICIAN Ê16 NO
60 57 CLINICIAN Ê16 NO. 645
61 CLINICIAN Ê16 NO rt-pa Drip, Ship and Retrieve
62 59 CLINICIAN Ê16 NO. 645 mrs:modified Rankin Scale, FIM:Functional Independence Measure, BI:Barthel Index, NIHSS: National Institute of Health Stroke Scale, JCS:Japan Coma Scale
63 CLINICIAN Ê16 NO
64 61 CLINICIAN Ê16 NO. 645 No.
65 CLINICIAN Ê16 NO
66 63 CLINICIAN Ê16 NO. 645 Hurthle mci....., p<. Hurthle mci....., p<.
67 CLINICIAN Ê16 NO
68 65 CLINICIAN Ê16 NO
69 CLINICIAN Ê16 NO Brose MS, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 384, (2014) Schlumberger M, et al:lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med, 372, (2015)
70 67 CLINICIAN Ê16 NO. 645
71 CLINICIAN Ê16 NO
72 69 CLINICIAN Ê16 NO. 645
73 ②超音波検査 US 数の年度別推移 㻝㻥㻥㻡 㻝㻝㻘㻤㻝㻞 㻝㻥㻥㻢 㻝㻟㻘㻢㻣㻡 㻝㻥㻥㻣 㻝㻠㻘㻤㻤㻝 㻝㻥㻥㻤 㻝㻢㻘㻞㻤㻡 㻝㻥㻥㻥 㻝㻣㻘㻡㻥㻢 㻞㻜㻜㻜 㻝㻤㻘㻝㻤㻢 㻞㻜㻜㻝 㻞㻜㻘㻜㻟㻞 㻞㻜㻜㻞 㻞㻜㻘㻢㻞㻢 㻞㻜㻜㻟 㻞㻞㻘㻡㻣㻡 㻞㻜㻜㻠 㻞㻟㻘㻣㻤㻠 㻞㻜㻜㻡 㻞㻠㻘㻥㻞㻝 㻞㻜㻜㻢 㻞㻠㻘㻝㻥㻜 㻞㻜㻜㻣 㻞㻡㻘㻝㻡㻠 㻞㻜㻜㻤 㻞㻠㻘㻢㻟㻡 㻞㻜㻜㻥 㻞㻠㻘㻥㻟㻣 㻞㻜㻝㻜 㻞㻠㻘㻝㻞㻣 㻞㻜㻝㻝 㻞㻠㻘㻥㻞㻣 㻞㻜㻝㻞 㻞㻠㻘㻜㻣㻝 㻞㻜㻝㻟 㻞㻠㻘㻝㻜㻠 㻞㻜㻝㻠 㻞㻞㻘㻞㻥㻣 年 2004年以降はプラトーである ③細胞診検査数の年度別推移 㻝㻥㻥㻡 㻥㻜㻜 㻝㻥㻥㻢 㻝㻘㻜㻞㻝 㻝㻥㻥㻣 㻝㻘㻝㻠㻢 㻝㻥㻥㻤 㻝㻘㻝㻞㻟 㻝㻥㻥㻥 㻝㻘㻞㻞㻠 㻞㻜㻜㻜 㻝㻘㻜㻢㻠 㻞㻜㻜㻝 㻝㻘㻝㻢㻝 㻞㻜㻜㻞 㻝㻘㻜㻡㻝 㻞㻜㻜㻟 㻝㻘㻝㻡㻝 㻞㻜㻜㻠 㻝㻘㻝㻟㻝 㻞㻜㻜㻡 㻝㻘㻞㻠㻞 㻞㻜㻜㻢 㻝㻘㻝㻞㻜 㻞㻜㻜㻣 㻝㻘㻜㻢㻢 㻞㻜㻜㻤 㻝㻘㻜㻣㻡 㻞㻜㻜㻥 㻝㻘㻜㻟㻜 㻞㻜㻝㻜 㻥㻟㻣 㻞㻜㻝㻝 㻝㻘㻜㻝㻜 㻞㻜㻝㻞 㻥㻟㻣 㻞㻜㻝㻟 㻤㻢㻟 㻞㻜㻝㻠 㻤㻝㻣 年 2005年をピークに減少傾向にある これは針生検 CNB やマンモトーム MMT 検査の 増加によるものである (72) CLINICIAN Ê16 NO
74 71 CLINICIAN Ê16 NO. 645 LH-
75 CLINICIAN Ê16 NO RH agonist tachyphylaxis
76 73 CLINICIAN Ê16 NO. 645
77 CLINICIAN Ê16 NO News letter News letter
78 75 CLINICIAN Ê16 NO. 645
79 CLINICIAN Ê16 NO
80 77 CLINICIAN Ê16 NO. 645
81 CLINICIAN Ê16 NO
82 79 CLINICIAN Ê16 NO. 645
83 CLINICIAN Ê16 NO
84 81 CLINICIAN Ê16 NO. 645
85 CLINICIAN Ê16 NO
86 83 CLINICIAN Ê16 NO
87 CLINICIAN Ê16 NO
88 85 CLINICIAN Ê16 NO % 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
89 CLINICIAN Ê16 NO
90 87 CLINICIAN Ê16 NO. 645
91 CLINICIAN Ê16 NO End of Life care
92 89 CLINICIAN Ê16 NO. 645
93 CLINICIAN Ê16 NO Step 1 Step 5 Step 5
94 91 CLINICIAN Ê16 NO. 645
95 CLINICIAN Ê16 NO
96 93 CLINICIAN Ê16 NO. 645
97 CLINICIAN Ê16 NO
98 95 CLINICIAN Ê16 NO. 645
99 CLINICIAN Ê16 NO NHS End of Life Care Programme publication supported by NCPC :Advance Care Planning :A Guide for Health and Social Care Staff (2007) AdvanceCarePlanning.pdf
100 IBD 3I survey IBD RA RA RA conventional synthetic DMARDscsDMARDs 2015 SpA PsA JIA 97 CLINICIAN Ê16 NO. 645
101 CLINICIAN Ê16 NO Halichondrin B
102 99 CLINICIAN Ê16 NO. 645 VEHERI
103 CLINICIAN Ê16 NO
104 101 CLINICIAN Ê16 NO. 645 in vitro
105 CLINICIAN Ê16 NO Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet, 377 (9769), (2011) Ali AM, Ueno T, et al :Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer, 47 (15), (2011) Shaked Y, et al :Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell, 14 (3), (2008) Tozer GM, et al :Disrupting tumour blood vessels. Nat Rev Cancer, 5 (6), (2005) Funahashi Y, et al:eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci, 105 (10), (2014) Kajiyama H, et al:chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol, 31 (2), (2007) Li QQ, et al:twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res, 15 (8), (2009) Yoshida T, et al:eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition
106 signaling. J Biol Chem, 284 (34), (2009) activation of urokinase receptor-dependent cell transition (EMT) induced in breast cancer cells by Jo M, et al:reversibility of epithelial-mesenchymal 305 (2008) 1alpha promotes metastasis. Nat Cell Biol, 10 (3), 295- Yang MH, et al :Direct regulation of TWIST by HIF- (MET) states. Br J Cancer, 110 (6), (2014) 103 CLINICIAN Ê16 NO. 645
107 CLINICIAN Ê16 NO response rate progression-free survival overall survival quality of life
108 105 CLINICIAN Ê16 NO. 645 luminal vascular endothelial growth factor P< log-rank P= positive study
109 CLINICIAN Ê16 NO survival post-progression post-progression survival P=0.03 log-rank
110 107 CLINICIAN Ê16 NO. 645 P=0.01 log-rank response evaluation criteria in solid tumours
111 CLINICIAN Ê16 NO Seah DS, et al :Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw, 12 (1), (2014) Miller K, et al:paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357, (2007) Broglio KR, Berry DA:Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst, 101 (23), (2009) Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE):a phase 3 open-label randomised study. Lancet, 377, (2011) Twelves C, et al :Efficacy of eribulin in women with metastatic breast cancer:a pooled analysis of two phase 3 studies. Breast Cancer Res Treat, 148 (3), (2014) Watanabe J:Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world:a single institutional review. SpringerPlus, 4, 625 (2015)
112 CLINICIAN Ê16 NO
113
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
東洋医学雑誌
Vol.67 No.2 123-130, 2016 Akiyo GUSHI a Chihaya KORIYAMA b Ryo YOSHINAGA c Hiromi YANO c Junichi TSUMAGARI d Eiichi TAHARA c a Gushi Dermatological Clinic, 45-3 Higashiohsyoji, Satsumasendai city, Kagoshima
26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira
26 1 : 35 45 2017 1 2 2 2 2 2 2 2 2 1 1 2 Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hirayama 1, Yoko Nakajo 2, Akemi Saito 2, Rie Hatakeyama
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
_’£”R‡Ù‡©
29 31 38 2008 31 1) 2) 2) 3) 2) 1) 2008 302008 12 Activities of Daily Living ADL ADL 42 ADL ADL 1990 QOL Quality of Life QOL 1 QOL // 2 Activity of Daily Living ADL Performance Status PS ADL 3 1) 2) 3)
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- [email protected] http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
終末期癌患者に対する 輸液治療の是非
3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
<95DB8C9288E397C389C88A E696E6462>
2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko
NL10
Information September, 2006 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.10 September, 2006 3 2006 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb
52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2
2
2010 ANNUAL REPORT AIZAWA HOSPITAL 2 ANNUAL REPORT AIZAWA HOSPITAL 2 巻頭言 本年の大きな出来事はなんと言っても 3 月 11 日に起こったマグニチュード9 の東日本大震災であろう 被災された皆様には心からお見舞いを申し上げる この震災は想定外であるとされた 想定外 とは何か? 議論が沸騰したが結論も出ず うやむやのうちに収束してしまった感を持つのは私だけであろうか?
4703ALL01
473201010 *** (1999) 16 2017 20023 2 1 2 1220 (1999a),(1999b) (1998), (2002) (2003)(1999)(2003) Conjoint Analysis Conjoint Analysis Willingness to PayStandard gamble Time trade-off Rating Scale Willingness
図 1 緩和ケアチーム情報共有データベースの患者情報画面 1 患者氏名, 生年月日, 性別, 緩和ケアチームへの依頼内容について,2 入退院記録, 3カンファレンス ラウンド実施一覧,4 問題点のリスト,5 介入内容の記録. 図 2 緩和ケアチームカンファレンス ラウンドによる患者評価入力画面 (
2015; 10(2): 901 5 活動報告 緩和ケアチームデータベースの改良に向けた取り組み 渡邊裕之 1,4), 江藤美和子 2,4) 3,4), 山﨑圭一 1 2 3 4 受付日 2014 年 9 月 10 日 / 改訂日 2015 年 1 月 29 日 / 受理日 2015 年 2 月 3 日 2011 年に, ベルランド総合病院緩和ケアチーム ( 以下,PCT) で構築した PCT 情報共有データベース
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
1. Sugimura, T. and Fujimura, S.: Tumor production in glandular stomach of rat by N-methyl-N'-nitro- N-nitrosoguanidine. Nature, 216, 943-944, 1967. 2. Fujimura, S., Kogure, K., Sugimura, T. and Takayama,
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
The Japanese Journal of Health Psychology, 29(S): (2017)
Journal of Health Psychology Research 2017, Vol. 29, Special issue, 139 149Journal of Health Psychology Research 2016, J-STAGE Vol. Advance 29, Special publication issue, 139 149 date : 5 December, 2016
日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Depa
Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Department of Obstetrics and Gynecology, Kobe University
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
審査報告書(案)
19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
_念3)医療2009_夏.indd
Evaluation of the Social Benefits of the Regional Medical System Based on Land Price Information -A Hedonic Valuation of the Sense of Relief Provided by Health Care Facilities- Takuma Sugahara Ph.D. Abstract
Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004
The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
